Home > Teva offers $40 billion for Mylan

Business
Teva offers $40 billion for Mylan

Description

Generic drugmaker Teva Pharmaceutical is offering $82 a share, or $40 billion, for its smaller rival Mylan, in an alternative to Mylan's deal to buy Perrigo. Bobbi Rebell reports.

Added on the 21/04/2015 23:20:41 - Copyright : Reuters EN

To customise your video :

Generic export code

More videos on the subject

Teva buys Allergan for $40.5 billion

Analysts say Allergan's betting it'll get further growth from its branded drugs business by selling its generics unit, so look for more deals. Fred Katayama reports.

27/07/2015 - Reuters EN
MIT claims Trump’s border wall would likely cost up to $40 billion

The MIT Technology Review is questioning Donald Trump’s claim that his proposed border wall will cost $12 billion. According to MIT, the cost could be closer to $40 billion.

07/11/2016 - Reuters - Next Media
Mylan offers discounts on EpiPen after Clinton criticism

Mylan said it would reduce the out-of-pocket cost of its severe allergy treatment EpiPen through a discount program, a day after Democratic Presidential candidate Hillary Clinton criticized the drug's high price. Bobbi Rebell reports.

26/08/2016 - Reuters EN
Mylan offers discounts on EpiPen after Clinton criticism

Mylan said it would reduce the out-of-pocket cost of its severe allergy treatment EpiPen through a discount program, a day after Democratic Presidential candidate Hillary Clinton criticized the drug's high price. Bobbi Rebell reports.

25/08/2016 - Reuters EN
Teva plans to boost stake in Mylan

Reuters has learned Teva looks to buy more shares in Mylan. Sources say that could allow Teva to take Mylan to court in the Netherlands. Fred Katayama reports.

03/06/2015 - Reuters EN